Glenmark Generics has announced that United States Food and Drug Administration (US FDA) has granted tentative approval for rizatriptan benzoate tablets, an anti-migraine drug, its generic version of Merck’s Maxalt tablets. According to IMS Health for the 12 month period ending June 2012, t Rizatriptan Benzoate immediate release tablets achieved sales of $ 315 million.
Glenmark’s current portfolio consists of 81 products authorised for distribution in the US marketplace and 41 ANDA’s pending approval with the US FDA.
EP News Bureau
- Advertisement -
